Psilocybin; Board of Pharmacy to reschedule upon federal scheduling changes.

The header metadata was updated to reflect the bill's final enrolled status for the 2026 session, replacing the 'Offered for Consideration' placeholder.

A non-substantive formatting change was made to the section number, changing '§ 54.1-3443' to '§ 54.1-3443' (adding a space after the section symbol).

Removed the mandate for the Board of Pharmacy to promulgate new regulations allowing for the prescribing, dispensing, and use of psilocybin.

Changed the primary action required of the Board of Pharmacy from creating new rules to rescheduling the drug consistent with federal changes.

Updated the trigger for action from FDA approval alone to include a 30-day waiting period after the FDA's final rule is published in the Federal Register.